Q-omics provides the consensus-scored TMEM89 profile across patient tissues and cancer cell-line models. TMEM89 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMEM89 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TMEM89 RNA expression shows 11,088 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCEC, COAD, and ESCA as cancer lineages where TMEM89 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM89 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM89 survival associations across molecular data types. TMEM89 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM89 RNA expression–survival associations across cancer types. High TMEM89 expression shows unfavorable associations in KIRC, ACC and MESO, but favorable associations in UCEC, SKCM and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TMEM89 RNA expression.
This table summarizes TMEM89 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM89. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM89 shows higher tumor expression in COAD, HNSC, LIHC, UCEC, STAD and BLCA. The COAD box plot shows higher TMEM89 RNA expression in tumor versus normal tissue (log2 FC = +0.607, t-test p < 0.001).
This table shows molecular features associated with TMEM89 in patient tissues and cancer cell lines. In patient samples, TMEM89 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM89 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
